Bio & Pharma
S.Korean biotech firm Genesystem to bring molecular testing to India
Production in India will secure its place in the Indian public procurement market, giving it the ability to deliver products to the public more efficiently
By Feb 08, 2023 (Gmt+09:00)
1
Min read
Most Read
Hankook Tire buys $1 bn Hanon Systems stake from Hahn & Co.
NPS to hike risky asset purchases under simplified allocation system
Osstem to buy Brazil’s No. 3 dental implant maker Implacil
S.Korea's LS Materials set to boost earnings ahead of IPO process
UAE to invest up to $1 bn in S.Korean ventures
Genesystem, a South Korean biotech firm specializing in on-site molecular testing platforms, announced on Tuesday its entry into the Indian market through a local sales and production partnership with an unnamed Indian company.
The deal will allow the company to supply its diagnostic products for infectious diseases, including the UF300 and UF340 diagnostic equipment, and more than 10 million diagnostic kits to India through a distributor agreement. Genesystem, however, declined to disclose the size of the contract or the supply period.
The firm is focused on developing diagnostic products for diseases prevalent in India such as tuberculosis, hepatitis B, hepatitis C, and HIV, with tuberculosis being the primary target.
In line with the Indian government's "Make in India" policy, Genesystem also intends to set up a local production base to reduce costs and streamline licensing procedures through localization.
Genesystem believes that production in India will secure its place in the Indian public procurement market, giving it the ability to deliver products to the public more efficiently.
Write to In-Hyuk Park at hyuk@hankyung.com
More to Read
-
Food & BeverageJeju Samdasoo enters India, ships 45 tons of mineral water
Dec 01, 2022 (Gmt+09:00)
1 Min read -
Mergers & AcquisitionsNaver, Mirae Asset ramp up investment in India’s promising startups
Oct 28, 2021 (Gmt+09:00)
4 Min read
Comment 0
LOG IN